Updates are available Correction dated 2025-09-22
Click to view Correction: https://doi.org/10.1038/s41598-025-19773-2
-
Authors
Lee, Daniel D.
Telfer, Kevin A.
Davis, Deanna L.
Smyth, Leon C.D.
Ravindran, Rahul
Czepielewski, Rafael S.
Huckstep, Christopher G.
Du, Siling
Kurashima, Kento
Jain, Ajay K.
Kipnis, Jonathan
Zinselmeyer, Bernd H.
Randolph, Gwendalyn J.
-
Funding
Funding for this research was provided by:
National Institute of Aging (PO1AG078106)
National Institute of Aging (PO1AG078106)
National Institute of Aging (PO1AG078106)
Crohn’s and Colitis Foundation (938100)
National Institute of Allergy and Infectious Diseases (U01AI163064)
National Institute of Diabetes and Digestive and Kidney Diseases (DP1DK130660)
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 19 August 2025
First Online: 29 August 2025
Change Date: 22 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-19773-2
Declarations
:
: Washington University and D.D.L., D.L.D., R.S.C., B.H.Z., and G.J.R. have filed a provisional patent on ADAPT-3D. ADAPT-3D solutions are being commercially developed by Leinco Technologies, Inc., Saint Louis, Missouri ( ). J. K. is cofounder of Rho Bio that aims to develop therapeutics for the lymphatic vasculature. Other authors declare no competing interests.
